FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042433238> ?p ?o ?g. }

• W3042433238 endingPage "2660" @default.
• W3042433238 startingPage "2657" @default.
• W3042433238 abstract "Abstract Background The combination lopinavir/ritonavir is recommended to treat HIV-infected patients at the dose regimen of 400/100 mg q12h, oral route. The usual lopinavir trough plasma concentrations are 3000–8000 ng/mL. A trend towards a 28 day mortality reduction was observed in COVID-19-infected patients treated with lopinavir/ritonavir. Objectives To assess the plasma concentrations of lopinavir and ritonavir in patients with severe COVID-19 infection and receiving lopinavir/ritonavir. Patients and methods Mechanically ventilated patients with COVID-19 infection included in the French COVID-19 cohort and treated with lopinavir/ritonavir were included. Lopinavir/ritonavir combination was administered using the usual adult HIV dose regimen (400/100 mg q12h, oral solution through a nasogastric tube). A half-dose reduction to 400/100 mg q24h was proposed if lopinavir Ctrough was &gt;8000 ng/mL, the upper limit considered as toxic and reported in HIV-infected patients. Lopinavir and ritonavir pharmacokinetic parameters were determined after an intensive pharmacokinetic analysis. Biological markers of inflammation and liver/kidney function were monitored. Results Plasma concentrations of lopinavir and ritonavir were first assessed in eight patients treated with lopinavir/ritonavir. Median (IQR) lopinavir Ctrough reached 27 908 ng/mL (15 928–32 627). After the dose reduction to 400/100 mg q24h, lopinavir/ritonavir pharmacokinetic parameters were assessed in nine patients. Lopinavir Ctrough decreased to 22 974 ng/mL (21 394–32 735). Conclusions In mechanically ventilated patients with severe COVID-19 infections, the oral administration of lopinavir/ritonavir elicited plasma exposure of lopinavir more than 6-fold the upper usual expected range. However, it remains difficult to safely recommend its dose reduction without compromising the benefit of the antiviral strategy, and careful pharmacokinetic and toxicity monitoring are needed." @default.
• W3042433238 created "2020-07-23" @default.
• W3042433238 creator A5006621304 @default.
• W3042433238 creator A5016950617 @default.
• W3042433238 creator A5020798181 @default.
• W3042433238 creator A5026385940 @default.
• W3042433238 creator A5029595668 @default.
• W3042433238 creator A5033220238 @default.
• W3042433238 creator A5036902332 @default.
• W3042433238 creator A5043182712 @default.
• W3042433238 creator A5047124634 @default.
• W3042433238 creator A5048145311 @default.
• W3042433238 creator A5057058749 @default.
• W3042433238 creator A5061527531 @default.
• W3042433238 creator A5081087142 @default.
• W3042433238 creator A5088300926 @default.
• W3042433238 creator A5091034850 @default.
• W3042433238 date "2020-07-20" @default.
• W3042433238 modified "2023-10-17" @default.
• W3042433238 title "Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients" @default.
• W3042433238 cites W1987818325 @default.
• W3042433238 cites W1995687174 @default.
• W3042433238 cites W2106786687 @default.
• W3042433238 cites W2116635252 @default.
• W3042433238 cites W2141163306 @default.
• W3042433238 cites W2158830353 @default.
• W3042433238 cites W3003322996 @default.
• W3042433238 cites W3010488079 @default.
• W3042433238 cites W3012379316 @default.
• W3042433238 doi "https://doi.org/10.1093/jac/dkaa261" @default.
• W3042433238 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7454557" @default.
• W3042433238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32688374" @default.
• W3042433238 hasPublicationYear "2020" @default.
• W3042433238 type Work @default.
• W3042433238 sameAs 3042433238 @default.
• W3042433238 citedByCount "11" @default.
• W3042433238 countsByYear W30424332382020 @default.
• W3042433238 countsByYear W30424332382021 @default.
• W3042433238 countsByYear W30424332382022 @default.
• W3042433238 crossrefType "journal-article" @default.
• W3042433238 hasAuthorship W3042433238A5006621304 @default.
• W3042433238 hasAuthorship W3042433238A5016950617 @default.
• W3042433238 hasAuthorship W3042433238A5020798181 @default.
• W3042433238 hasAuthorship W3042433238A5026385940 @default.
• W3042433238 hasAuthorship W3042433238A5029595668 @default.
• W3042433238 hasAuthorship W3042433238A5033220238 @default.
• W3042433238 hasAuthorship W3042433238A5036902332 @default.
• W3042433238 hasAuthorship W3042433238A5043182712 @default.
• W3042433238 hasAuthorship W3042433238A5047124634 @default.
• W3042433238 hasAuthorship W3042433238A5048145311 @default.
• W3042433238 hasAuthorship W3042433238A5057058749 @default.
• W3042433238 hasAuthorship W3042433238A5061527531 @default.
• W3042433238 hasAuthorship W3042433238A5081087142 @default.
• W3042433238 hasAuthorship W3042433238A5088300926 @default.
• W3042433238 hasAuthorship W3042433238A5091034850 @default.
• W3042433238 hasBestOaLocation W30424332381 @default.
• W3042433238 hasConcept C112705442 @default.
• W3042433238 hasConcept C126322002 @default.
• W3042433238 hasConcept C142462285 @default.
• W3042433238 hasConcept C159047783 @default.
• W3042433238 hasConcept C2777182164 @default.
• W3042433238 hasConcept C2779134260 @default.
• W3042433238 hasConcept C2779298103 @default.
• W3042433238 hasConcept C2781392899 @default.
• W3042433238 hasConcept C2781413609 @default.
• W3042433238 hasConcept C2993143319 @default.
• W3042433238 hasConcept C3008058167 @default.
• W3042433238 hasConcept C3013748606 @default.
• W3042433238 hasConcept C524204448 @default.
• W3042433238 hasConcept C71924100 @default.
• W3042433238 hasConcept C90924648 @default.
• W3042433238 hasConcept C98274493 @default.
• W3042433238 hasConceptScore W3042433238C112705442 @default.
• W3042433238 hasConceptScore W3042433238C126322002 @default.
• W3042433238 hasConceptScore W3042433238C142462285 @default.
• W3042433238 hasConceptScore W3042433238C159047783 @default.
• W3042433238 hasConceptScore W3042433238C2777182164 @default.
• W3042433238 hasConceptScore W3042433238C2779134260 @default.
• W3042433238 hasConceptScore W3042433238C2779298103 @default.
• W3042433238 hasConceptScore W3042433238C2781392899 @default.
• W3042433238 hasConceptScore W3042433238C2781413609 @default.
• W3042433238 hasConceptScore W3042433238C2993143319 @default.
• W3042433238 hasConceptScore W3042433238C3008058167 @default.
• W3042433238 hasConceptScore W3042433238C3013748606 @default.
• W3042433238 hasConceptScore W3042433238C524204448 @default.
• W3042433238 hasConceptScore W3042433238C71924100 @default.
• W3042433238 hasConceptScore W3042433238C90924648 @default.
• W3042433238 hasConceptScore W3042433238C98274493 @default.
• W3042433238 hasFunder F4320320893 @default.
• W3042433238 hasIssue "9" @default.
• W3042433238 hasLocation W30424332381 @default.
• W3042433238 hasLocation W30424332382 @default.
• W3042433238 hasOpenAccess W3042433238 @default.
• W3042433238 hasPrimaryLocation W30424332381 @default.
• W3042433238 hasRelatedWork W2001632090 @default.
• W3042433238 hasRelatedWork W2007858332 @default.
• W3042433238 hasRelatedWork W2010487097 @default.
• W3042433238 hasRelatedWork W2010497382 @default.

• next